Abstract: Long-term anti-epileptic drug (AED) therapy compromises bone health. Although vitamin D deficiency is proposed to be involved, it alone is not held responsible. This accounts for investigating other mechanisms in bone accrual. Recent studies have shown modulation of inhibitors of wnt pathway, sclerostin and dickkopf-1 (DKK-1), in glucocorticoids-induced osteoporosis. We investigated whether AED monotherapy modulates wnt inhibitors in Indian women with epilepsy. Women of age > 20-40 years with the diagnosis of epilepsy and receiving AEDs (carbamazepine, valproate and levetiracetam) for at least a year were enrolled. The results were compared with age-matched healthy controls with no evidence of metabolic bone disease. Women undergoing treatment with AEDs (mean duration: 50.59 AE 37.929 months) exhibited higher serum sclerostin and receptor activator of nuclear factor j B ligand (RANKL) and lower vitamin D (25-hydroxy vitamin D) and DKK-1 levels when compared to age-matched healthy controls. Sclerostin showed a positive correlation with RANKL, while DKK-1 presented no such relationship. However, no association was evident after adjusting for age, duration of treatment and total daily dose. Although a correlation between wnt inhibitors and RANKL could not be obtained, AEDs displayed changes in serum levels of wnt inhibitors in persons with epilepsy and hence these drugs may compromise bone health through a disturbance in wnt signalling mechanisms.
People with epilepsy are prone to falling prey to bony consequences, owing to seizure-related falls [1] or persisting comorbid complications such as ataxia, immobility, reduced physical activity and restricted sun exposure or as an adverse effect of chronic anti-epileptic drug (AED) therapy [2] . On an average, 50% of persons with epilepsy have bone abnormalities (ranging from 4 to 70% in different studies) [3] . AEDs affect people of all gender and age, however, women are additionally burdened with bone adversity due to the fact that women have lower peak bone mass and smaller bones than men and they lose bone mass more rapidly due to cessation of ovarian function at menopause [4] . The International Osteoporosis Foundation estimates that osteoporosis affects about 200 million women worldwide. About 61% of osteoporotic fractures occur in women, with a female to male ratio of 1.6 [5] .
Early studies revealed that metabolic bone diseases are associated with enzyme-inducing AEDs [phenytoin, carbamazepine (CBZ), oxcarbazepine] due to increased metabolism of vitamin D leading to its inactivation, with hyperparathyroidism and hypocalcaemia appearing as secondary manifestations. But this hypothesis could not explain the adverse bony consequences arising due to sodium valproate (SVP) and most of the newer generation AEDs (non-inducers). Later studies reported bone loss involving other mechanisms, including direct effect on osteoblasts and osteoclasts, vitamin K deficiency, low levels of calcitonin, altered sex-steroid and sex-hormone binding globulin metabolism, modulation of aromatase activity, hyperhomocysteinaemia [6] [7] [8] . Despite advances in understanding the mechanisms of AEDs-induced bony consequences, there exists a dichotomy in the reports of AEDs on bone adversities showing reduced bone mineral density (BMD) [9] [10] [11] or no change [12, 13] .
The bone metabolism can be assessed using bone turnover markers. They not only reflect the bone quality or fracture risk, but aids in understanding the pathophysiology of metabolic bone disease and secondary osteoporosis and guides in treatment selection and monitoring the response to a treatment. The role of wnt signalling in bone loss was recognized only after 2001 when a group of experiments revealed that loss-of-function mutations in the low density lipoprotein receptor-related protein 5 (LRP5) co-receptor cause the autosomal recessive disorder osteoporosis-pseudoglioma syndrome, which is characterized by low bone mass, ocular defects and a predisposition to fractures [14] . Wnt signalling pathway assists osteoblast differentiation from mesenchymal progenitors and promotes bone mass and strength. It is regulated by endogenous regulators, including sclerostin, Wnt inhibitory factor-1, members of secreted frizzled-related protein and dickkopf (DKK). b-Catenin, an agonist of Wnt Author for correspondence: Divya Vohora, Department of Pharmacology, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi 110062, India (e-mails divyavohora@hotmail.com and dvohra@jamiahamdard.ac.in).
signalling, has been found to regulate osteoprotegerin (OPG) production in mature osteoblasts and affects bone resorption without affecting osteoblast numbers. The accumulated b-catenin translocates into the nucleus and induces the expression of OPG to inhibit receptor activator of nuclear factor j B-RANK-ligand-mediated (RANK-RANKL) osteoclastogenesis [15] . Although the modulation of Wnt inhibitors following either anti-osteoporotic drugs such as raloxifene [16] , teriparatide [17] and bisphosphonates [17, 18] or proosteoporotic treatments such as glucocorticoids [19] has been reported, their possible modulation in AEDs-associated bone loss has not been studied. This study has provided first evidence of any such association between wnt inhibitors and anti-epileptic therapy.
Materials and Methods
Subjects. A total of 32 women were enrolled into the study fulfilling the following inclusion criteria: females of age > 20-40 years, diagnosis of epilepsy, receiving SVP, CBZ or levetiracetam (LTM) as monotherapy for at least a year and written informed consent ( fig. 1 ). The women were excluded due to the following reasons: conditions known to affect bone and mineral metabolism (such as primary hyperparathyroidism, Paget's disease, multiple myeloma, hepatic or renal disorders, diabetes mellitus, thyroid diseases, malignancy or malabsorption), co-administration of glucocorticoids, vitamin D or calcium and/or anti-osteoporotic drugs that are known to affect bone and mineral metabolism, persons in which AEDs are prescribed for conditions other than epilepsy, persons with smoking or drinking habit, postmenopausal women and those who refuse to give consent. The results were compared with age-matched healthy controls, with no evidence of metabolic bone disease. The design of the study was cross-sectional (analytic type). Women were recruited from the Neuroscience Centre at All India Institute of Medical Sciences (AIIMS), New Delhi, India ( fig. 1 ).
Study variables. Demographic and clinical characteristics of the study population were evaluated including age, weight, history of fractures, alcohol or tobacco consumption and associated co-morbidities. Also, the frequency and type of seizures, age at seizure onset, age at onset women of AED therapy and duration of therapy were recorded in all persons with epilepsy. Blood samples were obtained from the persons with epilepsy and healthy controls. Serum was separated, and the coded aliquots were stored at À80°C until biochemical analysis. Wnt inhibitors (Sclerostin and DKK-1) and RANKL were assayed using human-specific ELISA kit from Sincere Biotech (Beijing, People's Republic of China). Vitamin D [25-hydroxy vitamin D (25OHD)] kit was procured from Siemens (Mumbai, India). The intra-assay and inter-assay coefficients of variation for RANKL, sclerostin and DKK-1 were 9% and 15% and for 25OHD, 7% and 11.1%, respectively.
Randomization and blinding. Randomization was not used as the treatment of the persons with epilepsy was not intervened and they were grouped as per the treatment modality. It was not feasible to do blinding during enrolment as the decision regarding inclusion/exclusion was to be taken; however, the analysis was blinded. Serum was separated by a person not involved in patient recruitment and the aliquots were coded. Decoding was performed after the biochemical analysis.
Statistical analysis. Data contained both continuous and categorical variables. Therefore, mean AE S.D. or median with interquartile range was used for continuous data, whereas frequency with proportions was used for categorical data for their presentation. Normality of the continuous variables was tested by the Kolmogorov-Smirnov and Shapiro-Wilk tests. Student's t-test or the Mann-Whitney U-test was used for continuous variables at baseline comparisons between the cases and controls. Kruskal-Wallis 'H' was used for non-normal variables. The Spearman rank correlation was used to assess the correlation between the variables. Multiple linear regression was used to establish the relationship between sclerostin and RANKL and 25OHD by adjusting age, duration of treatment and total daily dose. Non-normal variables were first converted to log form before using it in the regression model. The two-sided p-value less than 0.05 was considered as statistically significant. The statistical software IBM SPSS version 22.0 (SPSS Inc, Chicago, USA) was used for the entire analysis.
No previous study has evaluated the effect of AEDs on Wnt antagonists; hence, the sample size was calculated based on the mean of DKK-1 from the first 15 persons of our study performed with the nMaster 1.0 software (Informer Technologies Inc., Madrid, Spain). The sample size calculation was thus carried out on the basis of mean DKK-1 values among the normal and persons with epilepsy undergoing AED therapy. The power of the study with 95% confidence interval was 95%.
Results
Demographics and clinical characteristics. age, 28.80 AE 6.048 years) receiving AEDs for 50.59 AE 37.929 months. Majority of the women (59.4%) were diagnosed with generalized tonic-clonic seizures. Persons were receiving monotherapy of either CBZ (n = 8), SVP (n = 10) or LTM (n = 14). There was no difference between the AEDtreated and healthy control group with regard to age. Twentyone (65.6%) women were seizure-free from last one year or more and 11 (34.4%) women still had seizures.
Biochemical and correlation analysis. Treatment with AEDs after a mean duration of 50.59 AE 37.929 months resulted in higher serum levels of sclerostin and RANKL and lower 25OHD and DKK-1 levels when compared to age-matched healthy controls (table 2) . We examined the correlations between wnt antagonists and RANKL and 25OHD in women receiving AEDs. Sclerostin had a significant positive correlation with RANKL while DKK-1 showed no such relationship ( fig. 2) . However, the positive correlation of sclerostin with RANKL as observed in table 3 showed no significant association after adjusting for age, duration of treatment and total daily dose in multiple linear regression analysis (table 3) .
Discussion
The present study demonstrated for the first time that wnt inhibitors are modulated in women with epilepsy receiving treatment with AEDs. However, there are differential effects with respect to the type of wnt inhibitor evaluated. Thus, while there were higher sclerostin levels in women with epilepsy undergoing AED therapy when compared with agematched healthy controls, DKK-1 levels showed a reduction. A similar trend was also reported previously when the effect of glucocorticoid therapy on wnt signalling antagonists was evaluated. Their study also showed a decline in DKK-1 levels, whereas sclerostin levels were higher compared with controls [19] . The authors of their study proposed a counter-regulatory mechanism to play a role in such differential effects. In another recent work on trans iliac bone biopsies obtained from patients with Crohn's disease and osteopenia, high levels of sclerostin were associated with inhibition of DKK-1 expression which was suggested to be possibly due to direct or indirect effects of increased sclerostin via lower bone formation [20] . Similarly, a study on chronic kidney disease patients demonstrated a positive association of sclerostin with bone mass while a negative association of DKK-1 with bone mass [21] . Thus, our results are in conformity with these studies.
The role of wnt antagonists (sclerostin and DKK-1) in bone adversities is proven through several studies. It is well-known that wnt signalling is known to induce differentiation of osteoblasts while suppressing the development of osteoclasts [15] . Over-expression of sclerostin gene in mice led to reduced bone mass due to alterations in bone formation process [22, 23] . Women receiving anti-osteoporotic therapies, either teriparatide or risedronate, for 6 months, showed reduced serum sclerostin levels in postmenopausal women [17] . In another study, women with severe osteoporosis treated with long-term alendronate and parathyroid hormone exhibited reduced circulating sclerostin levels [24] . Contrary to these reports, zoledronic acid was found to increase serum sclerostin levels indicating that sclerostin could play a role in coupling bone resorption to bone formation [25] .
RANKL belongs to the family of TNF pathway and is involved in the regulation of osteoclast formation and bone remodelling in both normal and pathological conditions. RANKL binds to the RANK receptors present on the osteoclast surface and aids in bone resorption through either osteoclastogenesis or activation of multinucleated mature osteoclasts [26] . Contrary to our findings, Bauer et al. reported no change after three months of AED treatment in a prospective study conducted on newly diagnosed epileptic adults [27] . The inconsistency in the results could be due to the fact that the longer duration of treatment in our study might register changes in the serum RANKL level which may fail to appear in short-term. Our findings are, however, in The results are expressed in numbers, % or mean AE S.D. AEDs, anti-epileptic drugs. agreement with other previous studies showing higher serum RANKL in women treated with AEDs and showing significant positive correlation with duration of treatment [28, 29] . Further, the positive correlation of sclerostin with RANKL observed in our study could be related to the fact that sclerostin regulates RANKL expression in osteocytes [30] while no such reports are available for DKK-1. The serum concentration of 25OHD reflects body stores of vitamin D and is commonly measured as an index of vitamin D repletion. We reported lowered 25OHD levels following treatment with all AEDs but none of our study participants were found to have vitamin D deficiency (as defined by 25OHD < 20 ng/mL) and showed vitamin D insufficiency (as defined by 25OHD levels between 20 and 30 ng/mL). Healthy controls reported vitamin D sufficiency (as defined by 25OHD levels between 30 and 50 ng/mL). Vitamin D is essential for calcium absorption and helps slow down the further bone loss. Previous studies with AEDs have reported abnormalities in indices of bone and mineral metabolism, including low serum concentrations of vitamin D and calcium with enzyme-inducing traditional AEDs (phenobarbitone, phenytoin and CBZ) [31, 32] and not with SVP [31] . Cytochrome P450 enzymeinducing AEDs accelerates the conversion of vitamin D to inactive metabolites. Newer studies, however, are not consistent with regard to significant hypovitaminosis D following AED treatment. A study by Pack et al. evaluated premenopausal women receiving AEDs for more than a year and reported reduced vitamin D with phenytoin but not with CBZ and SVP [33] . Similar outcomes were reported in a study conducted on children with epilepsy treated with monotherapy of CBZ, SVP or LTM for at least two years [34] . The higher sclerostin levels observed following AED therapy in our study and its positive correlation with RANKL suggest deteriorating effect on bone by inhibition of wnt signalling pathway. However, sclerostin levels are found to be significantly associated with age in pre-and postmenopausal women and in men [35, 36] . The increased sclerostin with age is suggestive of age-related impairment in bone formation, as sclerostin is a potential candidate as a biomarker for bone formation [37] . As age is a confounding factor for sclerostin levels, we reassessed the association after adjusting for age, duration of treatment and total daily doses. Surprisingly, no significant correlation was evident after controlling for these confounders. Thus, our study indicates that the effect of AEDs on wnt inhibitors and on RANKL and 25OHD may not be related to each other. Previously, the negative correlation of sclerostin with alkaline phosphatase, a bone formation marker, has been reported following glucocorticoid therapy [19] . However, their study did not assess the correlation taking into account the confounding factors such as age and thus the correlation reported in their study cannot be considered valid. We did not find any correlation of DKK-1 with either sclerostin or with RANKL and 25OHD. Our results are in agreement with a previous report where an association between sclerostin and DKK-1 expression was not observed [20] .
This study is unique because no other study has evaluated the effect of AEDs on wnt signalling. However, there are certain limitations of the study including the cross-sectional design, small sample size which limits the subgroup analysis of individual AEDs and lack of BMD data. These limitations may be overcome through a longitudinal and multi-centre study design. In summary, the present study showed that AED treatment displayed changes in the serum levels of wnt inhibitors in addition to RANKL and 25OHD and hence modulation of wnt inhibitors might be involved in their adverse effects on bone.
